Pramoxine

Summary

Pramoxine (CHEMBL1198) is an approved small-molecule local anaesthetic (ATC D04AB07); indicated across 2 conditions including hemorrhoid.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D04AB07 (+1 more)
• Indications: 2 conditions
• Chemistry: 293.4 Da · C17H27NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1198
Name	Pramoxine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4886
ChEBI	CHEBI:8357
ATC	D04AB07, C05AD07
Molecular formula	C17H27NO3
Molecular weight	293.4
InChIKey	DQKXQSGTHWVTAD-UHFFFAOYSA-N

SMILES: CCCCOC1=CC=C(C=C1)OCCCN2CCOCC2

IUPAC name: 4-[3-(4-butoxyphenoxy)propyl]morpholine

ChEBI definition: A member of the class of morpholines that is morpholine substituted at the nitrogen atom by a 3-(4-butoxyphenoxy)propyl group.

Pharmacological roles (ChEBI): local anaesthetic.

Also known as: Pramocaina, Pramocaine, SID11112434, Pramoxine, PRAMOXINE, PRAMOCAINE, PRAMOXINE HYDROCHLORIDE, pramocaine

Parent form; salt/anhydrous children: CHEMBL1201171

Patent coverage: 2,700 distinct patent families (10,295 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Sodium channel alpha subunits; brain (Types I, II, III), Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, 5-hydroxytryptamine receptor 2A, Voltage-gated inwardly rectifying potassium channel KCNH2, Histamine H3 receptor, Sigma non-opioid intracellular receptor 1, Cytochrome P450 1A2, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SIGMAR1	7.29	Ki	51	nM	CHEMBL_ACT_7717662
SIGMAR1	6.92	IC50	121	nM	CHEMBL_ACT_7717661
HRH3	5.61	AC50	2452	nM	CHEMBL_ACT_25200069
CHRM2	5.39	AC50	4045	nM	CHEMBL_ACT_25196273
KCNH2	5.12	AC50	7500	nM	CHEMBL_ACT_25118698
ALDH1A1	5.05	Potency	8912	nM	CHEMBL_ACT_4129941
HTR2B	5.03	AC50	9300	nM	CHEMBL_ACT_25164302

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hemorrhoid	4	MONDO:0004872	EFO:0009552

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).